Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.54 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.53 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4922206 | 0.83 | HRH3 (0.70) | HRH3CYP2D6HRH1CARM1SIGMAR1 | |
| SCHEMBL4917832 | 0.83 | HRH3 (0.77) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL5450398 | 0.81 | HRH3 (1.00) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL4937090 | 0.80 | HRH3 (0.97) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL3094803 | 0.80 | HRH3 (1.00) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL3082636 | 0.80 | HRH3 (1.00) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL4925369 | 0.80 | HRH3 (1.00) | HRH3CYP2D6HRH1CARM1 | |
| SCHEMBL3045956 | 0.79 | REV1 (0.70) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL3089244 | 0.79 | HRH3 (0.74) | HRH3CYP2D6HRH1ADRA1DADRA1A | |
| SCHEMBL3089241 | 0.79 | HRH3 (1.00) | HRH3CYP2D6HRH1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | claimed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009479-A1 | Tetrahydrobenzazepines as Histamine H3 Receptor Ligands | HRH3, HRH4, HRH1 | HRH3 1/4885CYP2D6 1722/4885HRH1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.